| HOME >> MEDICINE >> TECHNOLOGY |
$0.23 - $0.26 $
.62$
.44$
.51 $1.80 - $1.83 Inventory Step-up Amortization expense (d)0.060.02--0.08Adjusted Diluted Earnings Per Share
$0.29 - $0.32 $
.64$
.44$
.51 $1.88 - $1.91 Expected Fiscal 2012 Adjusted Earnings Per Share compared to Fiscal 2011 Adjusted Earnings Per Share(All Fiscal 2012 numbers presented are forecasted, subject to the Safe Harbor for Forward-looking Statements)Fiscal Year EndedJune 30, 2011Est. Fiscal Year EndedJune 30, 2012Increase from Prior YearEarnings Per Share - GAAP
$
.23 $1.80 - $1.83 683% - 696%Acquired In-Process Research & Development (a)1.34-Inventory Step-up Amortization expense (d)-0.08Adjusted Diluted Earnings Per Share
$
.57 $1.88 - $1.91 20% - 22%Supplemental Sales DataThree Months Ended June 30, Year over Year % ChangeFiscal Year Ended June 30,Year over Year % Change($ millions)2011201020112010Biomaterial Sales - GAAP
$
.5$
4.9(23%)$
44.4$
52.1(15%)Cardiovascular Products
1.15.112.719.3Biomaterial Sales - excluding Cardiovascular (e)$
.4$
9.87%$
31.7$
32.8(3%)Adjusted Effective Tax RateFiscal Year EndedEffective TaxJune 30, 2011RateNet Income - GAAP
$
2.1(4%)Acquired In-Process Research & Development (a)11.935%Net Income - As Adjusted
$
3.931%(a) Diluted earnings per share for the fiscal year ended June 30, 2011 included acquired in-process research and development (IPR&D) pre-tax charges of approximately $18.2 million ($11.9 million net of
'/>"/>
| SOURCE Kensey Nash Corporation Copyright©2010 PR Newswire. All rights reserved |